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Abstract: Treatment options for patients with multiple myeloma (MM) have increased during
the past decade. Despite the significant advances, challenges remain on which combination
strategies will provide the optimal response for any given patient. Defining optimal combination strategies and corresponding companion diagnostics, that will guide clinical decisions are
required to target relapsed or refractory multiple myeloma (RRMM) in order to improve disease
progression, survival and quality of life for patients with MM. Elotuzumab is a humanized
monoclonal antibody that targets signaling lymphocytic activation molecule F7 (SLAMF7),
approved by the US Food and Drug Administration (FDA) in 2015 and the European Medicines
Agency in 2016 for the treatment of MM. SLAMF7 is expressed in normal and malignant plasma
cells and has lower expression on natural killer (NK) cells. Experimental evidence indicates
that elotuzumab exhibits anti-myeloma activity through 1) antibody-dependent cell-mediated
cytotoxicity, 2) enhancing NK cells cytotoxicity and 3) interfering with adhesion of MM cells to
bone marrow stem cells (BMSCs). Although elotuzumab has no single agent activity in patients
with RRMM who have received one to three prior therapies, the combination of elotuzumab
with anti-myeloma agents, such as immunomodulatory drugs-lenalidomide, or proteasome
inhibitors (PIs)-bortezomib, remarkably improved the overall response rates and progressionfree survival in MM patients with only minimal incremental toxicity. In brief, the clinical data
for elotuzumab indicate that targeting SLAMF7 in combination with the use of conventional
therapies is feasible and effective with a tolerable safety profile for the treatment of RRMM.
Keywords: elotuzumab, SLAMF7, relapsed/refractory multiple myeloma (RRMM)
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Multiple myeloma (MM) is the second most common hematologic malignancy, featuring abnormal proliferation of plasma cells in the bone marrow. Although the etiology
of MM remains unknown, patients with MM often suffer end-organ damage, including hypercalcemia, renal disease, anemia and bone lesions, also known as the CRAB
characteristics.1,2 Factors associated with a poorer prognosis include: 1) age, who are
>65 years of age; 2) gender: men who are at slightly greater risk than women; 3) race:
African Americans who are more susceptible than white Americans; 4) those with
a family history of MM; 5) obesity/overweight and 6) those with a history of other
plasma cell diseases.3,4
Patients with MM who are <65 years of age, treated with high-dose therapy
and autologous stem cell transplantation (ASCT) have improved progression-free
survival (PFS) and overall survival (OS) compared with patients who do not receive
ASCT. Many patients with myeloma are elderly or have comorbid conditions which
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may not allow for ASCT.4 New approaches for MM treatment, especially immunomodulatory drugs (IMiDs) and
proteasome inhibitors (PIs), appear to improve response
and extend survival.5 Although the mortality rates of MM
have declined in the past decade, the overall incidence rate
of MM continues to increase, and <50% of patients are alive
for 5 years after their initial diagnosis.6 Current challenges
in the clinical management of MM include resistance to PIs
and IMiDs and tolerability. The estimated median OS of the
patients with MM who are refractory to PIs and IMiDs is ~9
months and the median event-free survival is <5 months.7,8
Monoclonal antibodies (mAbs) designed to target highly
expressed antigens on cells have emerged as a potential strategy for targeted cancer therapies. More than 10 mAbs were
approved by the US Food and Drug Administration (FDA)
for various solid tumor and hematological malignancies since
1997. Understanding lineage or tumor restricted expression
of surface receptors could lead to increased specificity of
antibody strategies for killing tumor cells. Indeed, compared
with standard chemotherapy, this antibody-targeted approach
has shown efficacy with less severe toxicities.9
Recently, a number of novel agents with different mechanisms of action have been developed based on an increased
knowledge of the pathophysiology of MM, including new
generations of PIs, IMiDs, mAB, vaccines, other immunotherapies, histone deacetylase inhibitors, alkylating agents,
kinase inhibitors, and the heat shock protein inhibitors.10–15
Therapeutic mABs may directly induce growth inhibition
A

by interfering with receptor–ligand interactions, induce
antibody-dependent cellular cytotoxicity (ADCC) stimulate
apoptosis signaling cascades, or act as a carrier of chemotherapy (antibody drug conjugate) or radioisotopes.
Elotuzumab is a humanized mAB indicated in MM
patients after failure of one to three prior therapies. Eotuzumab was granted “Breakthrough Therapy” designation for
MM by the FDA in May 2014 and was approved by FDA in
November 2015 and by European Medicines Agency in May
2016 for patients with RRMM. Elotuzumab was labeled for
use with combination chemotherapy to treat MM.

Mechanism of action of elotuzumab
The mechanisms of action of elotuzumab include 1) enhancing natural killer (NK) cells’ cytotoxicity through the Fab
portion of elotuzumab binding to signaling lymphocytic
activation molecule F7 (SLAMF7) receptor on NK cells; 2)
elotuzumab binds to SLAMF7 receptor on MM cells and
CD16 receptor on NK cells that activate NK cells to kill MM
cells by mediating ADCC and 3) elotuzumab inhibits MM
cells to interact with bone marrow stromal cells (BMSCs)
(Figure 1). Blockade of the CD16 (Fc receptor) on NK cells
or depletion of NK cells from peripheral blood mononuclear
cells (PBMCs) significantly inhibits elotuzumab-mediated
ADCC activity. There is no effect on elotuzumab-mediated
ADCC by depleting T cells, B cells or monocytes from
PBMCs, suggesting ADCC induction by elotuzumab is
dependent on NK cells.16
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Figure 1 Mechanism of action of elotuzumab.
Notes: (A) Elotuzumab activates NK cells directly through the binding of SLAMF7 expressed on NK cells; (B) elotuzumab binds to SLAMF7 receptor on MM cells and
CD16 receptor on NK cells to mediate the killing of MM cells through ADCC; and (C) elotuzumab inhibits MM cells to interact with BMSCs by binding SLAMF7 expressed
on MM cells.
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; BMSCs, bone marrow stem cells; MM, multiple myeloma; NK, natural killer; SLAMF7, signaling
lymphocytic activation molecule F7.

308

submit your manuscript | www.dovepress.com

Dovepress

Cancer Management and Research 2017:9

Dovepress

In coculture experiments, elotuzumab treatment or reducing the expression of SLAMF7 interfered with MM cell
adhesion to BMSCs, suggesting elotuzumab may reverse
cell adhesion-mediated drug resistance associated with
conventional therapies.17–19

Preclinical experiences with
elotuzumab
HuLuc63, later named elotuzumab, is a humanized anticell
surface 1 (CS1) mAb, which recognizes the extracellular
domain of CS1 (also known as SLAMF7). HuLuc63 significantly abrogated the growth of the human myeloma cell line
OPM2 using a murine xenograft model by ADCC induction.
The antitumor activity is related to the presence of functional
NK cells.16
CS1 belongs to the SLAM family and was found to be
highly expressed in malignant and normal plasma cells. CS1
is also expressed on the CS of NK cells, NK-like T cells,
CD8-positive T cells, mature dendritic cells and activated
B cells but was not found on other normal tissues.16,20,21
Expression of CS1 is frequent in MM cell lines (mRNA 45
of 45; protein 14 of 15 are expressed). CS1 was detected
in the majority of MM specimens (98 of 101), but not in
healthy donors and is one of the critical regulators of immune
response contributing to survival regulation in MM. Due to
restricted expression of SLAMF7; elotuzumab demonstrates
minimal adverse effects (AEs) on normal tissue, suggesting
a high therapeutic index in MM.21
Lenalidomide (Celgene Corporation; Summit, NJ, USA)
is a highly effective IMiD approved for MM patients.22–24
Evidence has shown that antitumor activity of lenalidomide
is through multiple mechanisms including enhancement of
T-cell and NK-cell activations, repression of angiogenesis,
altering cytokine production and direct inhibition of tumor
cell growth.25–27
Lymphocyte function-associated antigen 1, also known
as LFA-1 (CD11a/CD18) is an adhesion molecule. LFA-1
is a requirement for the adhesion of NK cells to target
cells through binding to intercellular adhesion molecule
(ICAM‑1). The interaction of LFA-1 and ICAM-1 is associated with multidrug resistance induction in vitro. Using antiCD18 mAb to interrupt LFA-1/ICAM-1 interaction decreased
elotuzumab activity as a single agent or in combination with
lenalidomide-using both cell MM cell death and NK activity
as endpoint measurements.28,29 Together, these data suggest
that elotuzumab-induced cell death and NK activity is partially dependent on LFA-1 function on NK cells.
The combination of elotuzumab with lenalidomide
enhanced antiproliferative effect more than elotuzumab or
Cancer Management and Research 2017:9
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lenalidomide monotherapy using either in vitro or in vivo
models of MM.30 This enhanced anti-myeloma activity correlated with NK activation, increased cytokine secretion and
LFA-1/ICAM-1 interaction.31,32
Bortezomib (Takeda Pharmaceutical Company, Osaka,
Japan) is the first PI approved for MM patients.31 Evidence
indicated that bortezomib sensitized myeloma cell lines and
primary myeloma cells to elotuzumab-mediated ADCC.
Moreover, the combination of elotuzumab and bortezomib
significantly increased anti-myeloma activity compared with
single agent in the OPM2 MM xenograft model.33
In addition to direct effects on the myeloma cell, bortezomib was shown to downregulate major histocompatibility
complex class I expression on the MM cell lines and patient
MM cells leading to enhanced sensitivity of MM cells to
NK cell-mediated lysis.32 The increase in NK-mediated lysis
may contribute to the favorable anti-myeloma response when
elotuzumab is combined with bortezomib. CS1 (SLAMF7)
RNA and protein expressions of patients with MM (n=103)
resulted in no significant change on the CS after bortezomib
administration, compared with the untreated group indicating
that changes in CS expression of CS1 do not correlate with
increased activity of the combination treatment regimen.
Taken together, the preclinical data suggest that elotuzumab is an attractive agent to combine with conventional
therapies such as lenalidomide and bortezomib.

Clinical experiences with
elotuzumab
Monotherapy
The first-in-human study of elotuzumab was designed as a
monotherapy to evaluate the safety, tolerability and pharmacokinetic and pharmacodynamic properties of elotuzumab
in patients with RRMM. Thirty-five patients were enrolled
and received escalating doses of elotuzumab from 0.5 to
20 mg/kg by intravenous (IV) infusion on an every 14 days
scheme. According to European Group for Bone and Marrow Transplantation myeloma response criteria, 26.5% (n=9)
patients had stable disease, also the best-observed response.
However, no objective responses were observed in this trial.
Collectively the preclinical and early clinical data suggested
that elotuzumab alone, albeit safe, was not sufficient to produce tumor response in RRMM but maybe a candidate for
combination strategy.34

Combination therapy
Preclinical studies demonstrated that elotuzumab in combination with other agents, including lenalidomide and
bortezomib showed increased antitumor activity compared
submit your manuscript | www.dovepress.com
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to single agent treatment.21,33 To evaluate the maximum
tolerated dose (MTD), efficacy, safety of elotuzumab in
combination with lenalidomide and dexamethasone. A Phase
I study of elotuzumab at a dose of 5, 10 and 20 mg/kg with
lenalidomide and low-dose dexamethasone in patients with
RRMM yielded an overall response rates (ORRs) of 82% (23
of 28); the median time to progression (TTP) had not been
reached after a median of 16.4 months of follow-up in the 20
mg/kg cohort.35 Another Phase I/II, multicenter, open-label
multiple-dose, dose escalation study investigated MTD safety
and efficacy of elotuzumab in combination with bortezomib in patients with RRMM (ClinicalTrials.gov Identifier:
NCT00726869). Twenty-eight patients with a median of two
prior therapies were enrolled and received escalating doses
of elotuzumab from 2.5 to 20 mg/kg IV and bortezomib (1.3
mg/m2 IV). The ORR was 48% (n=13) and 63% (n=17) of
patients achieved a minor response or better. The median TTP
was 9.46 months. Two of three (66.7%) patients who were
bortezomib-refractory previously showed objective response
with the addition of elotuzumab. Seventy percent (7 of 10)
of patients with high-risk cytogenetics showed an objective
response. MTD was not observed at the maximum planned
dose of 20 mg/kg of elotuzumab.36
The above Phase I results were encouraging- and elotuzumab-based combination therapy proceeded into Phase
II trials. In a Phase II study, 73 patients with RRMM were
enrolled (median age 63 years; range 39–82) and treated
with elotuzumab 10 mg/kg, n=36 or 20 mg/kg, n=27 plus
lenalidomide and low-dose dexamethasone. The ORR was
84% (10 mg/kg group was 92% and 20 mg/kg group was
76%); the median PFS was 29 months (10 mg/kg group was
32 months and 20 mg/kg group was 25 months).37 Owing to
the safety and excellent efficacy at a lower dose, 10 mg/kg
of elotuzumab was selected as the dosage for the Phase III
trials, ELOQUENT-1 and ELOQUENT-2.38
The ongoing Phase III ELOQUENT-1 trial is a randomized, open-label study comparing lenalidomide/low-dose
dexamethasone alone or in combination with elotuzumab
in newly diagnosed MM. The primary end point is PFS and
secondary end points include ORR and OS. This trial started
in May 2011, and the estimated enrollment is 750 patients
and the estimated study completion date will be July 2019
(ClinicalTrials.gov Identifier: NCT01335399).
The ongoing Phase III ELOQUENT-2 trial is a randomized, open-label study to assess whether the addition of
elotuzumab to lenalidomide/low-dose dexamethasone will
increase the PFS in patients with RRMM. Patients with
RRMM were randomized to the control arm (lenalidomide/
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dexamethasone alone) and the elotuzumab arm (elotuzumablenalidomide/dexamethassone) (ClinicalTrials.gov Identifier:
NCT01239797). The interim analysis of ELOQUENT-2
published in 2015, noted a total of 646 patients, with median
age of 66 years, 32% with high-risk 17p deletion, 9% with
t(4;14), were randomized to the elotuzumab group (n=321)
and the control group (n=325). Patients had previously
received one to three lines of therapy involving bortezomib
(70%), ASCT (55%), melphalan (65%), thalidomide (48%)
and lenalidomide (6%).38
Patients received 28-day cycles of lenalidomide 25 mg
orally (days 1–21) and dexamethasone 40 mg weekly with
or without elotuzumab 10 mg/kg IV (days 1, 8, 15 and 22 in
the first two cycles and days 1 and 15 from cycle 3). Therapy
was administered until disease progression or unacceptable
toxicity. The median PFS was 19.4 months in elotuzumab
group and 14.9 months in control group (HR, 0.70; 95%
CI=0.57–0.85; p=0.004). The 3-year PFS rate was 26% with
elotuzumab group versus 18% with the control group (HR
0.73; 95% CI=0.60–0.89; p=0.0014).39 ORR in elotuzumab
group (79%) was significantly higher than control group
(66%), p=0.002.38
ELOQUENT-3 is an open-label, Phase II trial, in which
patients with RRMM are randomized to the control arm
(pomalidomide/dexamethasone) or the elotuzumab arm
(elotuzumab/pomalidomide/dexamethasone). It is, currently,
recruiting participants and the estimated enrollment is 121
patients and the estimated study completion date is March
2019 (ClinicalTrials.gov Identifier: NCT02654132).
Mateos et al conducted a Phase II study evaluating the
safety and tolerability of elotuzumab 10 mg/kg combined
with thalidomide 50–200 mg and dexamethasone 40 mg
(with/without cyclophosphamide 50 mg) (ClinicalTrials.
gov Identifier: NCT01632150). Forty patients were enrolled
having received a median of three previous regimens,
including bortezomib (98%) and lenalidomide (73%).
Patients received 28-day cycles and continued until disease progression or unacceptable toxicity. Thalidomide
was administered 50 mg orally for the first 2 weeks, escalated to 100 mg for the next 2 weeks and beginning with
cycle 2–200 mg, once daily. Elotuzumab (10 mg/kg) was
administered as an IV weekly for the first two cycles and
beginning with cycle 3. Dexamethasone was administered
40 mg orally weekly on those weeks when elotuzumab
was not administered and 28 mg orally plus 8 mg IV on
elotuzumab dosing weeks. The patients who did not have a
partial response or better by the end of cycle 4 also received
cyclophosphamide (50 mg).
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Those patients did not have a partial response or better
by the end of cycle 4 also received cyclophosphamide, 50
mg. The ORR was 38%; the median PFS was 3.9 months; the
median OS was 16.3 months and 1-year OS rate was 63%.
The addition of elotuzumab to thalidomide and dexamethasone with or without cyclophosphamide resulted in minimal
incremental toxicity; suggesting that elotuzumab is well
tolerated in combination regimens used to treat RRMM.40
The proof-of-concept, randomized, open-label, Phase
II study investigated the efficacy and safety of elotuzumab
plus bortezomib/dexamethasone (EBd) and bortezomib/
dexamethasone (Bd) in patients with RRMM. A total of
152 patients (median age 66 years) with RRMM who had
received one to three prior therapies were randomized to
either EBd (n=77) or Bd group (n=75). EBd and Bd were
administered until disease progression or unacceptable
toxicity occurred. The results of EBd group and Bd group
are as follows, the ORR: 66% versus 63%; the 1-year PFS:
39% versus 33%; the 2-year PFS: 18% versus 11% and the

median PFS: 9.7 months versus 6.9 months, the OS: 51%
versus 47%, respectively. EBd-treated patients homozygous
for the high-affinity FcγRIIIa V allele (13 patients) had higher
PFS than EBd-treated patients homozygous for the lowaffinity FcγRIIIa F allele (24 patients), 22.3 months versus
9.8 months, respectively. Comparing the EBd group and Bd
group, elotuzumab improved clinical benefit with limited
added toxicity in patients with RRMM (ClinicalTrials.gov
Identifier: NCT021478048).41 Major clinical trials of elotuzumab are listed in Table 1. As shown in Table 1, the clinical
development path of elotuzumab received a breakthrough
therapy designation and quickly approved under FDA’s priority review process for therapeutic use in combination with
lenalidomide and dexamethasone for patients with MM who
have received from one to three prior therapies.

Pharmacokinetics/pharmacodynamics
Maximum elotuzumab serum concentration (Cmax) increased
in a dose-proportional manner from 5 to 20 mg/kg. But nonlin-

Table 1 Major clinical trials of elotuzumab
NCT no.

Phase

Patient population

Regimen

Result

Status

References

Monotherapy
NCT00425347

1

35 patients with RRMM

Dose escalation E (0.5–20
mg/kg)

CS1 receptor saturation:
10–20 mg/kg; ORR: 0%

Completed

34

Combination therapy
NCT00742560

1b

28 patients with RRMM

Completed

35

NCT00742560

2

Completed

36

NCT02654132
(ELOQUENT-3)
NCT01632150

2

NCT01478048

2

NCT01335399
(ELOQUENT-1)

3

NCT01239797
(ELOQUENT-2)

3

2

Dose escalation E (5–20 mg/ ORR: 82%; median PFS:
kg) plus L and D
32.9 months
73 patients with RRMM
E (10 mg/kg) plus L and D ORR: 92%; median PFS:32
months
estimated enrolment of 121 E (10 and 20 mg/kg) plus P
patients with RRMM
and D
40 patients with RRMM
E (10 mg/kg) plus T and D ORR: 38%; 1 median PFS:
3.9 months; median OS:
6.3 months; 1-year survival
rate: 63%
152 patients with RRMM
E (10 mg/kg) plus B and D ORR: 66%; 1-year PFS
rate:39%; 2-year PFS rate
18%; median PFS: 9.7
months
B and D
ORR: 63%; 1-year PFS
rate:33%; 2-year PFS rate
11%; median PFS: 6.9
months
estimated enrolment of
E (10 and 20 mg/kg) plus L
750 patients with newly
and D
diagnosed MM
646 patients with RRMM
E (10 mg/kg) plus L and D ORR: 79%; 1-year PFS rate:
68%; 2-year PFS rate: 41%;
median PFS: 19.4 months
L and D
ORR: 66%; 1-year PFS rate:
57%; 2-year PFS rate: 29%;
median PFS: 14.9 months

Recruiting
Active, not
recruiting

38

Active, not
recruiting

41

Active, not
recruiting
Active, not
recruiting

37

Abbreviations: B, bortezomib; D, low dose dexamethasone; E, elotuzumab; L, lenalidomide; MM, multiple myeloma; NCT, clinical trial registry; ORR, objective response
rate; OS, overall survival; P, pomalidomide; PFS, progression-free survival; RRMM, relapsed or refractory multiple myeloma; SLAMF7, signaling lymphocytic activation
molecule F7.
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ear pharmacokinetics (area under the curve [AUC]) increased
more than proportionally. The systemic clearance (CL)
decreased and terminal phase half-life (T1/2λ) increased with
increasing doses, indicating a saturation of target-mediated
elimination. Saturation of CS1 receptor by elotuzumab on
bone marrow plasma cells achieved 80% and 95% at doses
of 10 and 20 mg/kg, respectively, without dose-limiting toxicity (DLT). Bortezomib addition did not affect CS1 receptor
saturation. No clinically significant differences were found
in the pharmacokinetics of elotuzumab based on age (37–88
years), gender, race, baseline lactate dehydrogenase, renal
impairment, end-stage renal disease and mild hepatic impairment (the mean terminal half-life is 33 days).34,36

Safety and tolerability
In Phase 1 study, the MTD of IV elotuzumab in combination with oral lenalidomide and dexamethasone is identified,
28 patients were enrolled. Three doses of elotuzumab were
given, three patients each for 5 and 10 mg/kg and 22 patients
for 20 mg/kg. There was no DLT at 5, 10 and 20 mg/kg of
elotuzumab in first cycle. Elotuzumab in combination with
lenalidomide and low-dose dexamethasone was, generally,
well tolerated. Based on the efficacy data, 10 mg/kg of elotuzumab by IV infusion is recommended to combine with
lenalidomide and low-dose dexamethasone.34
In Phase 3 ELOQUENT-2 trail, patients were randomly
assigned to receive elotuzumab plus lenalidomide/dexamethasone (elotuzumab group), or lenalidomide/dexamethasone
alone (control group). The median duration of treatment was
17 and 12 months in the elotuzumab and control groups,
respectively. Serious adverse reactions were reported in 65%
of the elotuzumab group and 57% in the control group. The
most common grade 3 or 4 hematological AEs included
lymphocytopenia in 77% versus 49% and neutropenia in
34% versus 44%, in the elotuzumab and control groups,
respectively. The treatment-related AEs in the elotuzumab
arm versus the control arm were fatigue (47% vs 39%),
pyrexia (37% vs 25%), peripheral edema (26% vs 22%),
nasopharyngitis (25% vs 19%), diarrhea (47% vs 36%),
constipation (36% vs 27%), musculoskeletal or connectivetissue disorders included muscle spasms (30% vs 26%), back
pain (28% vs 28%); the other disorders included cough (31%
vs 18%) and insomnia (23% vs 26%).38

Future directions and conclusion
Although MM remains incurable, treatment options have
improved for patients during the past decade. Myeloma is
a genetically diverse disease and thus has provided chal312
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lenges for the implementation of precision medicine and
targeted therapy. A better understanding of biomarkers that
predict response to specific therapeutic regimens is needed to
improve patient care.42 Utilization of CS markers specific for
plasma cells has gained interest for directing the treatment of
MM since additional targets and therapeutic antibodies are
emerging. For example, daratumumab binds to CD38 which
is highly expressed on MM cells and was recently approved
for patients with MM. CD38 is less abundant on normal lymphoid and myeloid cells. Daratumumab exerts anti-myeloma
activity by multiple immune-mediated mechanisms including
complement-dependent cytotoxicity, ADCC and apoptosis
induction.43,44 It is feasible that combined targeting of CD38
and SLAMF7 may improve anti-myeloma activity as downregulation of both receptors may represent a rare event and
thus decreased probability of escape from ADCC.
The combination of elotuzumab with other mABs treatment is also being clinically evaluated. The PD-1 immune
checkpoint inhibitor nivolumab, has antitumor immune
response in various tumors and approval by the FDA for nonsmall cell lung cancer, melanoma, head/neck cancer, Hodgkin’s
lymphoma and renal cell carcinoma. In a Phase III multicenter
trial, patients with RRMM are randomly assigned to evaluate
the clinical benefit and safety for the combination therapy of
N-Pd group (nivolumab, pomalidomide and dexamethasone,
the investigational arm), Pd group (pomalidomide and dexamethasone, the control arm) and NE-Pd group (elotuzumab,
nivolumab, pomalidomide and dexamethasone, the experimental arm). This study is, currently, recruiting participants.
(ClinicalTrials.gov Identifier: NCT02726581).
In summary, elotuzumab has shown promising early clinical results and understanding how to best combine targeting
SLAMF7 in combination with other immune strategies as
well as standard of care agents may lead to improved patient
outcomes for the treatment of MM.
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